Linear increment in efficiency with the inclusion of surrogate endpoint

In a two-sample clinical trial, a fixed proportion of true-and-surrogate and the remaining only-surrogate responses are observed. We quantify the increase in efficiency to compare the treatments as a linear function of the proportion of available true responses.